EP 1664047 A1 20060607 - SUBSTITUTED INDOLIZINE 1,2,3,6,7,8 DERIVATIVES, FGFS INHIBITORS, A METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES
Title (en)
SUBSTITUTED INDOLIZINE 1,2,3,6,7,8 DERIVATIVES, FGFS INHIBITORS, A METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES
Title (de)
SUBSTITUIERTE INDOLIZIN-1,2,3,6,7,8-DERIVATE, FGFS-INHIBITOREN, EIN VERFAHREN ZU DEREN HERSTELLUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE DERIVATE ENTHALTEN
Title (fr)
DERIVES D'INDOLIZINE 1,2,3,6,7,8 SUBSTITUEE, INHIBITEURS DES FGFS, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
Publication
Application
Priority
- FR 2004002347 W 20040916
- FR 0310957 A 20030918
Abstract (en)
[origin: FR2859997A1] 1,2-Disubstituted 3-(3,4-disubstituted benzoyl)-indolizine derivatives (I) are new. Indolizine derivatives of formula (I) and their salts are new. [Image] R : H, halo, Me, OH, OA, COOH, COOA, NR 5R 6, NHSO 2A NHCOA, NHCOOA, -O-A'-COOR 7, -O-A'-NR 5R 6, -O(CH 2) nPh' or -CONR 5R 6, where R is in the 6-, 7- or 8-position of the indolizine ring system; A : 1-5C alkyl; A' : 1-5C alkylene; n : 0-5; R 5and R 6H, A or benzyl; R 7H or A; Ph' : phenyl (optionally substituted by one or more of halo, OA, COOH or COOA); R 1OA, COOH, COOA or Ph'; R 2A, 3-6C cycloalkyl or phenyl (optionally substituted by one or more of halo or OA); and R 3and R 4OH, OA, NH 2, COOH, COOA, NO 2, NR 5R 6, NHCOA, NHCOCF 3, CONR 5R 6or CONHOH; provided that if R = H, then R 1is not OA, COOH or COOA unless R 3or R 4= CONR 5R 6or CONHOH. An independent claim is also included for the preparation of (I). ACTIVITY : Cytostatic; cardiant; antiarteriosclerotic; vasotropic; antidiabetic; ophthalmological; antirheumatic; antiarthritic; antiinflammatory; osteopathic; anorectic. (I) are effective against implanted Lewis lung carcinoma in a mouse tumor angiogenesis model at oral doses of 0.1-100 mg/kg (no specific results for individual compounds given in the source material). MECHANISM OF ACTION : Fibroblast growth factor (FGF) inhibitor.
IPC 1-7
IPC 8 full level
A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 19/02 (2006.01); A61P 27/00 (2006.01); A61P 35/00 (2006.01); C07D 471/04 (2006.01)
CPC (source: EP US)
A61P 3/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 19/08 (2017.12 - EP); A61P 27/00 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); A61P 35/04 (2017.12 - EP); C07D 471/04 (2013.01 - EP US)
Citation (search report)
See references of WO 2005028476A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
FR 2859997 A1 20050325; FR 2859997 B1 20060203; AR 047486 A1 20060125; EP 1664047 A1 20060607; JP 2007505867 A 20070315; JP 4943150 B2 20120530; TW 200519113 A 20050616; US 2006199962 A1 20060907; US 7553845 B2 20090630; WO 2005028476 A1 20050331
DOCDB simple family (application)
FR 0310957 A 20030918; AR P040103342 A 20040917; EP 04787388 A 20040916; FR 2004002347 W 20040916; JP 2006526664 A 20040916; TW 93128233 A 20040917; US 37897206 A 20060317